NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy

Sex: All

Ages: 35 Years – 85 Years

Healthy volunteers: 1

Phase: NA

Enrollment: 6

Sponsor: Haukeland University Hospital

Summary

The objective of the NAD-brain study is to determine the blood and brain pharmacokinetics of NAD replenishment therapy (NRT) using Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN).

Eligibility Criteria

Inclusion Criteria:Age 30-85 years at the time of enrollment.Neurologically healthy at the time of enrollment.Exclusion Criteria:History of acute or chronic neurological disorder affecting the central nervous system (CNS). Migraine, cluster headache, and tension headache are allowed, but not on the day of the study visits.Impaired renal function.Impaired hepatic function.Severe hematological disease.Any psychiatric disorder that would interfere with compliance in the study.Any severe somatic illness that would make the individual unable to comply and participate in the study.Mitochondrial disease.Use of high dose vitamin B3 supplementation within 30 days of enrolment.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05698771). StuddyBuddy aggregates publicly available trial information.